Skip to main content
SpringerPlus

Table 2 Pathological response in breast [n (%)] following NAC

From: Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival

 

PATHOLOGICAL RESPONSE GRADE [n(%)]b*

GROUPS (n = 107)a

5(PCR)

4(MRD)

3(PR)

2/1(PoR/NR)

A

11 (30.6)

10 (27.8)

10 (27.8)

5 (13.9)

(n = 36)

B

15 (40.5)

10 (27)

9 (24.3)

3 (8.1)

(n = 37)

C

1 (5.6)

1 (5.6)

6 (27.8)

10 (16.1)

(n = 18)

D

2 (12.5)

2 (12.5)

5 (31.3)

7 (43.8)

(n = 16)

(A + C)

12 (22.2)

11 (20.4)

15 (27.8)

16 (29.6)

(n = 54)

(B + D)

17 (32.1)

12 (22.6)

14 (26.4)

10 (18.8)

(n = 53)

  1. aTwo patients received preoperative radiotherapy and one had no demonstrable cancer in the breast (involved ALN on presentation).
  2. bPCR : complete response, no residual invasive tumour cells in specimen, DCIS accepted (grade 5); MRD : minimal residual disease, >90% loss of tumour cells, (grade 4); PR : partial response, moderate reduction in tumour cell burden, between 30%-90% reduction in tumour cells (grade 3); PoR : poor response, minimal loss (<30%) of tumour cells, (grade 2); NR : no response/no change in overall cellularity, (grade 1).
  3. *Pathological responses were not significantly different between the Groups (p>0.05); A + C versus (v) B + D: χ2 = 3.717, p = 0.446 (Pearson Chi-Square Test).
Back to article page